Physician profile
David E Fritz
NPI 1396970331
$5,762.64
in general payments reported to CMS, 2019-2025
27 companies · $781 in 2025
The $781 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $499 · 2021: $596 · 2022: $813 · 2023: $885 · 2024: $1,532 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,140.18 | 2019-2025 | Relistor |
| Abbott Laboratories | $1,087.79 | 2019-2025 | Proclaim, Octrode, Eterna |
| Collegium Pharmaceutical, INC. | $657.82 | 2019-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $596.91 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $524.59 | 2020-2024 | Senza |
| Scilex Pharmaceuticals INC. | $515.59 | 2021-2025 | Ztlido |
| Protega Pharmaceutials INC | $185.71 | 2022-2025 | Roxybond |
| Zyla Life Sciences, INC. | $163.54 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $142.43 | 2024-2025 | |
| Pfizer INC. | $114.04 | 2019 | |
| Daiichi Sankyo INC. | $93.50 | 2019 | |
| Averitas Pharma INC. | $88.64 | 2024 | Qutenza |
| Biodelivery Sciences International, INC. | $80.23 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $46.97 | 2019 | |
| Arbor Pharmaceuticals, INC. | $45.83 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $45.76 | 2019 | |
| Pacira Therapeutics, INC. | $44.26 | 2019-2021 | |
| Lundbeck LLC | $31.78 | 2021-2025 | Vyepti |
| Amneal Pharmaceuticals LLC | $22.25 | 2023 | Lyvispah |
| Neuronetics, INC. | $22.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2020 | |
| Hikma Pharmaceuticals USA | $18.49 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.15 | 2023 | Horizant |
| Sentynl Therapeutics, INC. | $16.00 | 2019 | |
| Ibsa Pharma INC. | $14.91 | 2021 | |
| Virtus Pharmaceuticals LLC | $13.82 | 2020 | |
| Almatica Pharma LLC | $13.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fritz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.